Hoth Therapeutics to Resume ATM Stock Sales
Hoth Therapeutics, Inc. is preparing to resume sales of its common stock under its existing At the Market Offering Agreement with H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Hoth Therapeutics, Inc. is preparing to resume sales of its common stock under its existing At the Market Offering Agreement with H.C. Wainwright & Co., LLC. The company had previously suspended and terminated the prior prospectus supplement and related prospectus, but the underlying Sales Agreement remained in effect.
To restart these at-the-market offerings, Hoth will file a new prospectus supplement to its shelf registration statement on Form S-3 (File No. 333-291566), which was previously declared effective by the SEC on December 4, 2025. The filing also includes a legal opinion and consent from Sheppard, Mullin, Richter & Hampton LLP regarding the validity of the securities to be sold under the Sales Agreement.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Sales Agreement date: November 8, 2024
Form S-3 file number: File No. 333-291566
Form S-3 effectiveness date: December 4, 2025
+2 more
5 metrics
Sales Agreement date
November 8, 2024
Date of At the Market Offering Agreement with H.C. Wainwright
Form S-3 file number
File No. 333-291566
Shelf registration supporting ATM sales
Form S-3 effectiveness date
December 4, 2025
Date SEC declared the Form S-3 effective
8-K event date
April 16, 2026
Date Hoth decided to file new prospectus supplement
Exhibit 5.1
Legal opinion filed
Opinion of Sheppard Mullin on validity of securities
Key Terms
At the Market Offering Agreement, prospectus supplement, registration statement on Form S-3, emerging growth company, +1 more
5 terms
At the Market Offering Agreement financial
"relating to the potential issuance from time to time of the Company’s common stock pursuant to the At the Market Offering Agreement"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
prospectus supplement financial
"suspended its use of and terminated the prospectus supplement and related prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
registration statement on Form S-3 regulatory
"file a new prospectus supplement to its registration statement on Form S-3 (File No. 333-291566)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
legal opinion and consent financial
"The legal opinion and consent of Sheppard, Mullin, Richter & Hampton LLP relating to the validity of the securities"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Hoth Therapeutics (HOTH) announce in this 8-K filing?
Hoth Therapeutics announces plans to resume sales of its common stock under an existing At the Market Offering Agreement, supported by a new prospectus supplement to its effective Form S-3 shelf registration.
What is the At the Market Offering Agreement mentioned for HOTH?
The At the Market Offering Agreement is a sales arrangement dated November 8, 2024 between Hoth Therapeutics and H.C. Wainwright & Co., LLC, allowing the company to sell common stock into the market from time to time.
Why is Hoth Therapeutics filing a new prospectus supplement?
Hoth Therapeutics is filing a new prospectus supplement so it can resume issuing and selling common stock under its At the Market Offering Agreement using its existing Form S-3 shelf registration that is already effective with the SEC.
What role does Sheppard Mullin play in Hoth Therapeutics’ ATM program?
Sheppard, Mullin, Richter & Hampton LLP is providing a legal opinion and related consent on the validity of the securities that Hoth Therapeutics may sell under the At the Market Offering Agreement, which are listed as exhibits in the filing.
Which SEC registration statement supports Hoth Therapeutics’ resumed ATM sales?
The resumed at-the-market sales rely on Hoth Therapeutics’ shelf registration statement on Form S-3, File No. 333-291566, which the SEC previously declared effective on December 4, 2025 and now will be supplemented.
Did Hoth Therapeutics terminate its At the Market Offering Agreement?
Hoth Therapeutics terminated only the prior prospectus supplement and related prospectus, while the At the Market Offering Agreement with H.C. Wainwright & Co., LLC itself remained in full force and effect, enabling a restart via a new prospectus supplement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates